Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Trial to Evaluate the Safety and Tolerability of SYS6077 Injection in Participants With Advanced Malignant Tumor

NCT07873359 is registered in ClinicalTrials.gov with Beijing Kangchuanglian Biopharmaceutical Technology Research Co., Ltd as lead sponsor.

NCT NCT07873359
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07873359 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Trial to Evaluate the Safety and Tolerability of SYS6077 Injection in Participants With Advanced Malignant Tumor
Lead sponsor
Beijing Kangchuanglian Biopharmaceutical Technology Research Co., Ltd
Phase
Phase 1
Overall status
Not yet recruiting
Start date
November 22, 2026
Completion date
November 22, 2031
Enrollment
110 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors